Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation.
The experimental and pharmacological characteristics of various formulations of an anticancer agent (epirubicin, EPI) and lipiodol were evaluated in vitro and in vivo. Three forms of EPI-lipiodol, i.e., an oil-in-water type of emulsion (O/W type), a water-in-oil type of emulsion (W/O type), and a suspension (S type), were prepared and investigated for their stability. An O/W-type emulsion using a stock solution of Iopamidol as the solvent for EPI was the most stable form in the stationary state in vitro. In 16 patients with malignant liver tumors (14 hepatocellular carcinomas and 2 liver metastases), the three forms of EPI-lipiodol were injected into the proper hepatic artery. The plasma EPI level was monitored periodically and analyzed pharmacokinetically. No significant difference in the pharmacokinetics of EPI was detected among the O/W, W/O, and S types.
Kobayashi
S
S
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan.
Narimatsu
Y
Y
Ogawa
K
K
Hashimoto
S
S
Nakatsuka
S
S
Miura
H
H
Ohzono
H
H
Ka
W J
WJ
Ido
K
K
Hiramatsu
K
K
D000368:Aged; D000369:Aged, 80 and over; D016461:Chemoembolization, Therapeutic; D004355:Drug Stability; D015251:Epirubicin / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D015251:Epirubicin; D007459:Iodized Oil